Back to Search
Start Over
Efficacy of empagliflozin for weight and glycemic control of a patient with Prader-Willi syndrome, systemic lymphedema and extreme obesity: a case report.
- Source :
-
International journal of diabetes in developing countries [Int J Diabetes Dev Ctries] 2022 Oct; Vol. 42 (4), pp. 787-790. Date of Electronic Publication: 2022 Apr 27. - Publication Year :
- 2022
-
Abstract
- A patient with Prader-Willi syndrome (PWS), extreme obesity and hyperglycemia had her body weight increased considerably for 6 months, even with exercise and diet programs. Treatment with metformin and empagliflozin (12.5 mg/day) induced a weight loss of 14 kg (-10.3%) for 6 months and the reduction of glycated hemoglobin A <subscript>1c</subscript> .<br />Competing Interests: Conflict of interestThe authors declare no competing interests.<br /> (© The Author(s), under exclusive licence to Research Society for Study of Diabetes in India 2022.)
Details
- Language :
- English
- ISSN :
- 0973-3930
- Volume :
- 42
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- International journal of diabetes in developing countries
- Publication Type :
- Report
- Accession number :
- 35495777
- Full Text :
- https://doi.org/10.1007/s13410-022-01076-1